The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
U.S. FDA to decide whether to authorize a booster dose in the coming days
Time to combine innovation, access and technology to deliver positive patient outcomes
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)